IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
This Quarter Return
+14.44%
1 Year Return
+17.25%
3 Year Return
+11.14%
5 Year Return
+79.35%
10 Year Return
–
AUM
$257M
AUM Growth
+$257M
(-2.4%)
Cap. Flow
-$21M
Cap. Flow
% of AUM
-8.18%
Top 10 Holdings %
Top 10 Hldgs %
53.62%
Holding
74
New
14
Increased
16
Reduced
17
Closed
18
Top Buys
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$4.85M |
| 2 |
ADMS
Adamas Pharmaceuticals, Inc.
ADMS
|
$4.33M |
| 3 |
Sangamo Therapeutics
SGMO
|
$4.1M |
| 4 |
Neurocrine Biosciences
NBIX
|
$4.04M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
$3.88M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$7.11M |
| 2 |
Viatris
VTRS
|
$5.43M |
| 3 |
SHPG
Shire pic
SHPG
|
$5.4M |
| 4 |
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
|
$5.01M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$4.63M |
Sector Composition
| 1 | Healthcare | 91.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $26.3M | 10.24% | 180,522 +3,000 | +2% | +$437K |
|
2
Biogen
BIIB
$19.4B
| $22.4M | 8.71% | 71,508 +10,400 | +17% | +$3.25M |
|
3
Regeneron Pharmaceuticals
REGN
$61.5B
| $18.3M | 7.11% | 40,830 -7,300 | -15% | -$3.26M |
|
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $13.5M | 5.25% | 88,722 -46,800 | -35% | -$7.11M |
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $12.9M | 5.03% | 92,141 -4,500 | -5% | -$631K |
|
6
Incyte
INCY
$16.5B
| $10.4M | 4.04% | 88,975 +11,500 | +15% | +$1.34M |
|
7
Gilead Sciences
GILD
$140B
| $9.95M | 3.87% | 122,784 +1,000 | +0.8% | +$81K |
|
|
8
Acadia Pharmaceuticals
ACAD
$4.38B
| $9.07M | 3.53% | 240,773 +103,000 | +75% | +$3.88M |
|
|
ADMS
9
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $8.25M | 3.21% | 390,000 +204,766 | +111% | +$4.33M |
|
10
Amgen
AMGN
$155B
| $6.73M | 2.62% | 36,104 -14,000 | -28% | -$2.61M |
|
|
11
BioMarin Pharmaceuticals
BMRN
$11.2B
| $6.36M | 2.48% | 68,384 -49,782 | -42% | -$4.63M |
|
|
ENTL
12
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
| $6.3M | 2.45% | 341,468 | – | – |
|
13
Exelixis
EXEL
$10.1B
| $6.16M | 2.4% | 254,334 +47,334 | +23% | +$1.15M |
|
|
XLRN
14
DELISTED
Acceleron Pharma Inc.
XLRN
| $5.75M | 2.24% | 153,633 -24,010 | -14% | -$898K |
|
15
Sarepta Therapeutics
SRPT
$1.78B
| $5.49M | 2.14% | 121,000 +60,000 | +98% | +$2.72M |
|
|
PRTK
16
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $5.07M | 1.97% | 202,000 +144,000 | +248% | +$3.61M |
|
17
Halozyme
HALO
$8.56B
| $4.91M | 1.91% | 282,633 +78,000 | +38% | +$1.35M |
|
|
18
Alnylam Pharmaceuticals
ALNY
$58.5B
| $4.85M | 1.89% | +41,300 | New | +$4.85M |
|
|
CLVS
19
DELISTED
Clovis Oncology, Inc.
CLVS
| $4.61M | 1.8% | 56,000 +21,000 | +60% | +$1.73M |
|
|
TSRO
20
DELISTED
TESARO, Inc.
TSRO
| $4.52M | 1.76% | 35,000 +1,500 | +4% | +$194K |
|
|
21
Sangamo Therapeutics
SGMO
$157M
| $4.1M | 1.59% | +273,000 | New | +$4.1M |
|
|
22
Neurocrine Biosciences
NBIX
$13.8B
| $4.04M | 1.57% | +66,000 | New | +$4.04M |
|
23
Ligand Pharmaceuticals
LGND
$3.15B
| $3.95M | 1.54% | 29,000 +20,000 | +222% | +$2.72M |
|
|
FPRX
24
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $3.54M | 1.38% | 86,500 +45,500 | +111% | +$1.86M |
|
|
SGEN
25
DELISTED
Seagen Inc. Common Stock
SGEN
| $3.13M | 1.22% | 57,500 -7,500 | -12% | -$408K |
|